Related Experiment Videos
Effects of captopril on left ventricular systolic and diastolic function after acute myocardial infarction
C O Gøtzsche1, P Søgaard, J Ravkilde
1Department of Medicine and Cardiology, Aarhus University Hospital, Denmark.
Insights
Captopril treatment after acute myocardial infarction (AMI) prevented left ventricular (LV) dilatation and diastolic dysfunction. This heart failure medication improved ejection fraction in patients with early LV systolic dysfunction.
Area of Science:
- Cardiology
- Pharmacology
- Heart Failure Research
Background:
- Left ventricular (LV) dilation and dysfunction are significant complications following acute myocardial infarction (AMI).
- While captopril is known to prevent LV dilation, its impact on diastolic function post-AMI remains unclear.
- Early identification of LV systolic dysfunction is crucial for managing heart failure progression.
Purpose of the Study:
- To investigate the effect of captopril on left ventricular (LV) diastolic function in patients post-acute myocardial infarction (AMI).
- To assess captopril's impact on LV volume indexes and ejection fraction in AMI patients.
- To determine if captopril can prevent the development of diastolic dysfunction alongside systolic improvement.
Main Methods:
- A placebo-controlled, double-blind, parallel study involving 58 acute myocardial infarction (AMI) patients with heart failure or low ejection fraction.
- Patients were randomized to receive either placebo or captopril (25 mg twice daily) starting on day 7 post-AMI.
- Left ventricular (LV) volume indexes, ejection fraction, and peak filling flow velocities were assessed over a 6-month period.
Main Results:
- Captopril prevented LV dilation, showing no change in LV diastolic volume index and a 13% reduction in LV systolic volume index.
- The captopril group experienced a significant increase in ejection fraction, unlike the placebo group.
- Placebo patients showed reduced early filling velocities and an altered early-to-atrial filling ratio, indicating diastolic dysfunction, which was prevented by captopril.
Conclusions:
- Captopril effectively prevents left ventricular (LV) dilatation and preserves diastolic function in acute myocardial infarction (AMI) patients.
- The medication significantly improves ejection fraction, indicating enhanced systolic function post-AMI.
- Captopril offers a therapeutic benefit for AMI patients exhibiting early signs of LV systolic dysfunction and preventing diastolic impairment.
Abstract:
The left ventricle progressively dilates in some patients after acute myocardial infarction (AMI). Both systolic and diastolic left ventricular (LV) dysfunction can be of significance in the development of heart failure. Captopril has been shown to prevent dilatation, but the effect on LV diastolic function is unknown. In a placebo-controlled double-blind parallel study, 58 AMI patients with heart failure or low ejection fraction, or both, were consecutively randomized at day 7 to either placebo or captopril (25 mg twice daily). No differences were present between the groups at baseline. Fifty-three patients completed the 6-month study period. Both LV diastolic and systolic volume indexes increased significantly in the placebo group (17 and 14%, respectively); in the captopril group there was no change in LV diastolic volume index, but a 13% reduction in LV systolic volume index. Ejection fraction increased significantly in the captopril group. The peak flow velocities of the early and atrial filling phases were measured, and the ratio between the velocities was calculated. A significant reduction was observed during the study period in early peak flow velocity (65 to 52 cm/s) and in the ratio between early and atrial peak flow velocity (1.3 to 0.8) in the placebo group (p less than 0.05), but no significant changes occurred in the captopril group. No correlation was found between dilatation of the left ventricle and reduction in early peak flow velocity or the ratio between early and atrial peak flow velocity. In conclusion, captopril prevented LV dilatation, improved ejection fraction and prevented LV diastolic dysfunction in AMI patients with early signs of LV systolic dysfunction.